Protein Kinase Inhibitors: all 15,766 studies that test it

Page 20 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsRecruitingNCT05771181Phase 2
• DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.RecruitingNCT05770544Phase 2/3
• DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive CancersRecruitingNCT05770037Phase 2/3
• A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)RecruitingNCT05769660Phase 1
• A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 AlterationsRecruitingNCT05769075Phase 1
• Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsRecruitingNCT05768464Phase 2
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
• A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingNCT05766410Phase 2
• Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung CancerRecruitingNCT05765877Phase 2
• Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)RecruitingNCT05762640Phase 2
• Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingNCT05760612Phase 3
• Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingNCT05760378Phase 3
• Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 2
• The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute LeukaemiasRecruitingNCT05756322Phase 1/2
• Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GISTRecruitingNCT05751733Not applicable
• TR128 in Patients With Advanced Solid TumorsRecruitingNCT05751356Phase 1
• HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
• Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05751018Phase 2
• Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's ArteritisRecruitingNCT05749666Phase 3
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingNCT05749588Phase 2
• Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerRecruitingNCT05748834Phase 2
• A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingNCT05747729Phase 1/2
• Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerNot yet recruitingNCT05746728Phase 1/2
• Study of Sirolimus in IgG4-related DiseaseNot yet recruitingNCT05746689Not applicable
• Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine TumorsRecruitingNCT05746208Phase 2
• A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
• HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
• Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System TumorsRecruitingNCT05745623Phase 1/2
• Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast CancerRecruitingNCT05744687Phase 2/3
• Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell CarcinomaRecruitingNCT05738694Phase 3
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
• Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell CarcinomaRecruitingNCT05733715Early Phase 1
• The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
• Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant TumorsNot yet recruitingNCT05728541Phase 1
• Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementRecruitingNCT05727176Phase 2
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingNCT05723198Phase 3
• Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsNot yet recruitingNCT05722977Phase 2
• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3
• Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)RecruitingNCT05722795Not applicable
• Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical StudyRecruitingNCT05721651Phase 2
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingNCT05720260Phase 2
• TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingNCT05718167Phase 3
• A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingNCT05714072Phase 1
• Alectinib Pharmacokinetic in Patients With NSCLCRecruitingNCT05713006Phase 1/2
• Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced SarcomaRecruitingNCT05711615Phase 1
• Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerRecruitingNCT05706779Phase 2
• Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic MalignanciesRecruitingNCT05705505Phase 1/2
• Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
• Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
• Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessRecruitingNCT05691491Phase 1/2
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusRecruitingNCT05688696Phase 2
• Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal CordsRecruitingNCT05688488Phase 1/2
• Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid TumorsRecruitingNCT05687136Phase 1
• Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine TumorsRecruitingNCT05687123Phase 1
• Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingNCT05686434Phase 2
• Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy SubjectRecruitingNCT05684653Phase 1
• A Study of KC1036 in Patients with Advanced Thymic TumorsRecruitingNCT05683886Phase 2
• A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesRecruitingNCT05683717Phase 1
• Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomasRecruitingNCT05681195Phase 2
• Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue SarcomaRecruitingNCT05679921Phase 2
• A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic CholangiocarcinomaRecruitingNCT05678270Phase 2
• A Study of TY-1091 in Patients With Advanced Solid TumorsRecruitingNCT05675605Phase 1/2
• Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05675462Phase 1
• A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)RecruitingNCT05673928Phase 2
• TT-00973-MS Tablets in Patients With Advanced Solid TumorsNot yet recruitingNCT05673538Phase 1
• A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2
• AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular CarcinomaRecruitingNCT05669339Phase 2
• Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCRecruitingNCT05668962Phase 2
• Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLCNot yet recruitingNCT05668767Phase 2
• Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic HepatopathyRecruitingNCT05662813Phase 2
• Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver ImpairmentRecruitingNCT05661461Phase 1
• A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced CancerRecruitingNCT05659732Phase 1
• PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid CancerRecruitingNCT05659186Phase 2
• Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2
• HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05658640Phase 1/2
• Advanced or Metastatic CholangiocarcinomaNot yet recruitingNCT05653817Not applicable
• Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older SubjectsRecruitingNCT05653258Phase 2/3
• Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingNCT05652283Phase 2
• Efficacy and Tolerance of Baricitinib, a JAK Inhibitor, in the Treatment of Refractory Non-infectious Non-anterior UveitisNot yet recruitingNCT05651880Phase 3
• Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 AlterationsRecruitingNCT05651672Phase 2
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingNCT05646862Phase 3
• Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyEnrolling by invitationNCT05645536Phase 3
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic TumoursRecruitingNCT05644392Phase 1
• Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric CancerNot yet recruitingNCT05643677Phase 2
• A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationRecruitingNCT05641493Phase 1/2
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2
• Study to Assess Safety and Tolerability of Multiple Doses of EO2002RecruitingNCT05636579Phase 1
• Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1
• A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsRecruitingNCT05635487Phase 2
• Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell LymphomaRecruitingNCT05635162Phase 2
• The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal CancerNot yet recruitingNCT05634590Phase 2
• Testing for Safety and Colorectal Cancer Preventive Effects of ONC201RecruitingNCT05630794Phase 1
• Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingNCT05627232Phase 1
• A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast CancerNot yet recruitingNCT05621434Phase 2
• Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)RecruitingNCT05620628Phase 2
• Lenvatinib for Advanced Bone and Soft Tissue SarcomaRecruitingNCT05617859Phase 2
• Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
• Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT05613894Phase 1
• A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2

← Protein Kinase Inhibitors overview